Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #HealthCare #Medical #Pharmaceuticals #Appointment #NASDAQ #Investing
King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to...
http://dlvr.it/TP0HMf
http://dlvr.it/TP0HMf
Comments
Post a Comment